Brk has become an ideal cellular target for tumor therapy because it occurs in a majority of breast tumors but low or undetectable amounts of Brk occurs in normal tissues (Mitchell et al., 1994; Barker et al., 1997; Brauer and Tyner, 2010). Here, PTK6 is linked to neoplasm.